Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates reduced lung function decline with nintedanib in systemic sclerosis–associated interstitial lung disease, suggesting slowed pulmonary progression.
Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo. (Funded by Boehringer Ingelheim; SENSCIS ClinicalTrials.gov number, NCT02597933.).
No takes yet. Share an insight, caveat, or question.
Distler et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: